The program offers multiple perspectives on the HIV cure field, showcasing exciting recent research findings with potential for clinical translation.
The conference sessions will present the latest research and foster discussion on:
• The establishment of the HIV reservoir
• The adaptive and innate immune responses associated with HIV control
• The molecular characteristics of the viral reservoirs
• The development of new therapies
| SUNDAY 22 SEPTEMBER 2024 | |
|---|---|
| OPENING HIV CURE AND 2000HIV SYMPOSIUM Chaired by: Linos Vandekerckhove and Sarah Gerlo |
|
| 17.30 - 18.00 | Registration |
| 18.00 - 18.30 | Opening ceremony Linos Vandekerckhove, Ghent University, Ghent, Belgium |
| 18.30 - 19.00 | Plenary I: HIV cure research: current status and future directions Ole Søgaard, Aarhus University Hospital, Aarhus, Denmark |
| 19.00-19.30 | Plenary II: 2000HIV study André Van der Ven, Radboudumc, Nijmegen, the Netherlands |
| 19.30-20.30 | Perspectives on HIV cure Simon Collins, HIV i-Base, London, United Kingdom Charlotte Vanden Bulcke, Ghent University Hospital, Ghent, Belgium Marie-Angélique De Scheerder, Ghent University Hospital, Ghent, Belgium |
| 20.30 - 22.00 | Opening reception |
| MONDAY 23 SEPTEMBER 2024 | |
|---|---|
| PLENARY III Chaired by: Brad Jones and Sarah Palmer |
|
| 08.00 - 08.30 | Registration |
| 08.30 - 09.10 | Plenary III: How systems immunology can help to decipher human diseases Joachim L. Schultze, DZNE, University of Bonn, Bonn, Germany |
| SESSION 1 – ‘VIRAL INTEGRATION’: CHROMOSOMAL ARCHITECTURE Chaired by: Brad Jones and Sarah Palmer |
|
| 09.10 - 09.35 | HIV targeted integration in the context of the 3D genome organization Monsef Benkirane, Research Director CNRS, Montpellier, France |
| 09.35 - 10.00 | Integration site profiling : How? Where? And Consequences? Angela Ciuffi, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland |
| 10.00 - 10.25 | Identification of cellular factors as novel epigenetic regulators of HIV-1 gene expression Carine VAN LINT, Service of Molecular Virology, University of Brussels (ULB), Brussels, Belgium |
| 10.25 - 10.55 | Break |
| SESSION 2 – COMPOSITION AND EVOLUTION OF THE VIRAL RESERVOIR - Part 1 Chaired by: Monsef Benkirane and Jolien Vermeire |
|
| 11.00 - 11.25 | Composition of the reservoir in the 2000HIV study: clinical data and biomarker analysis Mareva Delporte and Kavita Mehta, Ghent University, Ghent, Belgium |
| 11.25 - 11.50 | Immune selection of proviral DNA by CTL responses Brad Jones, Weill Cornell Medicine, New York, United States |
| 11.50 - 12.15 | HIV expression in infected T cell clones Mary Kearney, HIV Dynamics & Replication Program, Center for Cancer Research, National Cancer Institute, United States |
| 12.15-12.40 | Understanding the viro-immunological mechanisms contributing to HIV control during an analytical treatment interruption Sarah Palmer, The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia |
| 12.40 - 14.00 | Lunch |
| SESSION 3 – COMPOSITION AND EVOLUTION OF THE VIRAL RESERVOIR - Part 2 Chaired by: Mary Kearney and Marion Pardons |
|
| 14.00 - 14.25 | Reactivation of the viral reservoir through nanoparticle-delivered Tat mRNA Daniel Claiborne, The Wistar Institute, Philadelphia, United States |
| 14.25 - 14.50 | Single infusion of stem like CCR5-modified CD4 T cells provide long- term HIV control Ashish Sharma, Emory University, Atlanta, United States |
| 14.50 - 1515 | Establishment of the viral reservoir during early infection Linos Vandekerckhove, Ghent University, Ghent, Belgium |
| 15.15-15.40 | Macrophage training reactivates latent HIV-1 from HAART-suppressed PBMCs of PLWH John Sinu, National Institutes of Health, Bethesda, United States |
| 15.40 - 16.10 | Break |
| SESSION 4– INSPIRATIONAL SESSION Chaired by: André Van der Ven |
|
| 16.15 - 17.00 | Satellite Session: ViiV Healthcare’s remission & cure program: a strategic scientific focus Andrew Zolopa, Richard Dunham, Allan Tenorio, ViiV Healthcare, United States |
| 17.00 - 17.45 | Plenary IV: Cues from the metabolome immune modulation and response to immunotherapies Rafick Sékaly, Emory University, Atlanta, United States |
| 18.00 - 20.00 | Poster session and poster contest with wining and dining |
| TUESDAY 24 SEPTEMBER 2024 | |
|---|---|
| PLENARY V Chaired by: Rogier Sanders and Sarah Gerlo |
|
| 08.30 - 09.10 | Plenary V: Sensing of the intestinal environment by the adaptive immune system Dan Littman, New York University School of Medicine and Howard Hughes Medical Institute, New York, United States |
| SESSION 5 – CELL AND IMMUNE BASED THERAPY TO ELIMINATE THE RESERVOIR (PART 1) Chaired by: Rogier Sanders and Sarah Gerlo |
|
| 09.10 - 09.35 | Lessons learned from the UCSF-amfAR combination HIV cure study Rachel Rutishauser, University of California, San Francisco, United States |
| 09.35 - 10.00 | Hybrid CAR-T cells: road to endurance Wojciech Witkowski, Ghent University, Ghent, Belgium |
| 10.00 - 10.25 | Gene therapy strategies to enhance and prolong HIV-specific immunity during virus latency Christopher Peterson, Fred Hutchinson Cancer Center, Washington, United States |
| 10.25 - 10.55 | Break |
| SESSION 6 – MODULATION OF INNATE IMMUNITY (PART1) Chaired by: Rafick Sékaly and Jan van Lunzen |
|
| 11.00 - 11.25 | The impact of infections and vaccination on aging of the immune system Mihai Netea, Radboudumc, Nijmegen, the Netherlands |
| 11.25 - 11.50 | Integrative omics reveal the genetic and molecular landscape of immune responses and comorbidities in people living with HIV Javier Botey Bataller, CiiM, Helmholtz Centre for Infection Research, Braunschweig, Germany |
| 11.50 - 12.15 | Exploring the potential of innate immune memory to achieve HIV control Jéssica dos Santos, Radboudumc, Nijmegen, the Netherlands |
| 12.15 - 12.40 | Impact of food intake on immune system and inflammation Quirijn de Mast, Radboudumc, Nijmegen, the Netherlands |
| 12.40 - 14.00 | Lunch |
| SESSION 7 – MODULATION OF INNATE IMMUNITY (PART 2) Chaired by: Dan Littman and Mihai Netea |
|
| 14.00 - 14.25 | Persistent inflammation in people treated during acute infection Sarah Gerlo, Ghent University, Ghent, Belgium |
| 14.25 - 14.50 | Unravelling molecular signatures and causal factors underlying latent cytomegalovirus infection among PLHIVs Yang Li, CiiM, Helmholtz Centre for Infection Research, Hannover, Germany |
| 14.50 - 15.15 | Residual viremia and cardiovascular disease Twan Otten, Radboudumc, Nijmegen, the Netherlands |
| 15.15 - 15.40 | Microbiome and HIV Jingyuan Yang-Fu, University Medical Center Groningen, the Netherlands |
| 15.40 - 16.10 | Break |
| SESSION 8 – CELL AND IMMUNE BASED THERAPY TO ELIMINATE THE RESERVOIR (PART 2) Chaired by: Wojciech Witkowski and Michael Peluso |
|
| 16.15 - 16.40 | Assessing immunogenicity barriers of the HIV-1 envelope trimer Rogier Sanders, Amsterdamumc, Amsterdam, the Netherlands |
| 16.40 - 17.05 | Beyond T-cell based therapeutic vaccines Beatriz Mothe, IrsiCaixa, Badalona, Spain |
| 17.05 - 17.30 | Implementing gene therapy studies in Africa Cissy Kityo, Joint Clinical Research Center, Kampala, Uganda |
| 19.00 - 22.00 | Speakers dinner |
| WEDNESDAY 25 SEPTEMBER 2024 | |
|---|---|
| PLENARY VI Chaired by: Carine Van Lint & Jolien Van Cleemput |
|
| 08.30 - 09.10 | Plenary VI: The impact of the diet-microbiota axis on immunity and cancer therapy Nicola Gagliani, University Medical Center Hamburg-Eppendorf, Hamburg Center for Translational Immunology (HCTI), Hamburg, Germany |
| SESSION 9 – HIV PERSISTENCE IN TISSUES Chaired by: Carine Van Lint & Jolien Van Cleemput |
|
| 09.10 - 09.35 | Towards understanding the in-situ interplay between HIV and host Constantinos Petrovas, University Hospital of Lausanne, CHUV, Lausanne, Switzerland |
| 09.35 - 10.00 | Phenotypic and virological characterization of the HIV-1 reservoir in matched blood and tissues Marion Pardons, Ghent University, Ghent, Belgium |
| 10.00 - 10.30 | Break |
| 10.35 - 11.00 | Role of tissue NK cells in HIV persistence Maria Buzon, Infectious Disease Department, Vall d´Hebron Research Institute, Barcelona, Spain |
| 11.00 - 11.25 | IFN and TGF-β epigenetic re-programing of trained immunity and virological control in SIV Susan Pereira, Emory University, Atlanta, United States |
| 11.25 - 12.00 | Future perspectives towards cure Jan van Lunzen, Radboudumc, Nijmegen, the Netherlands |
| 12.00 - 12.15 | Prize for best poster presentations & closing remarks Linos Vandekerckhove, Ghent University, Ghent, Belgium |